StockData

Eloxx Pharmaceuticals vs Prime Medicine

ELOX and PRME side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ELOX and PRME compare

Prime Medicine is the larger company, worth 15 times as much as Eloxx Pharmaceuticals ($696M against $47.4M).

Eloxx Pharmaceuticals scores higher on the StockData Score (7 against 5 for Prime Medicine), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricELOXPRME
Size and price
Market cap$47.4M$696M
Share price$11.74$3.84
Change, 1 year1067170%13.9%
Change, 5 years−98.1%−81.0%
Beta (5Y)–1.72
Employees7146
StockData Score
Total score7 (better)5
Valuation score1 (better)0
Growth score00
Performance score1 (better)0
Health score55
Dividend score00
Valuation
P/B1.0× (better)17.5×
FCF yield–−22.5%
Growth
Revenue growth (TTM)−100%–
Revenue growth, 5Y average–−2.3%
Profitability
Return on equity−54.3% (better)−373%
Financial health
Debt / equity0.000.00
Current ratio3.74 (better)3.05
Altman Z-score−4.60 (better)−5.80
Piotroski F-score34 (better)
Dividends and buybacks
Buyback yield0.00%–
Shareholder yield0.00%0.00%
Ownership
Held by institutions71.8%58.8%
Held by insiders42.6%18.6%
Short interest, % of float2.3%19.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.